Notice2023-20479
Government-Owned Inventions; Availability for Licensing and Collaboration
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 21, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention described below presents an advancement concerning osteoclast fusion; osteoclasts are responsible for human skeletal remodeling and their dysfunction is a key factor for both rare and common bone diseases. The invention covers methods for modulating osteoclast fusion and bone resorption through the Lupus autoantigen (La) protein. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, has conducted conceptual in-vitro studies and is now seeking potential licensees and collaborators for further development and advancement.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 182 (Thursday, September 21, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 182 (Thursday, September 21, 2023)]
[Notices]
[Page 65183]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-20479]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing and
Collaboration
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention described below presents an advancement
concerning osteoclast fusion; osteoclasts are responsible for human
skeletal remodeling and their dysfunction is a key factor for both rare
and common bone diseases. The invention covers methods for modulating
osteoclast fusion and bone resorption through the Lupus autoantigen
(La) protein. The Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD), National Institutes of Health,
has conducted conceptual in-vitro studies and is now seeking potential
licensees and collaborators for further development and advancement.
ADDRESSES: Inquiries relating to this licensing and collaboration
opportunity should be directed to: Heather Gunas, JD, MPH, Senior
Technology Transfer Manager, National Cancer Institute (NCI) Technology
Transfer Center, 9609 Medical Center Drive, Room 1E446, Rockville, MD
20850 (for overnight mail) or Bethesda, MD 20892 (for regular mail),
Telephone: (240) 276-5530; Facsimile: (240) 276-5504; Email:
<a href="/cdn-cgi/l/email-protection#b1d6c4dfd0c2d9f1dcd0d8dd9fdfd8d99fd6dec7"><span class="__cf_email__" data-cfemail="9ef9ebf0ffedf6def3fff7f2b0f0f7f6b0f9f1e8">[email protected]</span></a>. A Confidential Disclosure Agreement will be
required to receive copies of unpublished information regarding this
invention.
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are available for
licensing: PCT Application No. PCT/US22/018639, filed March 3, 2022,
and entitled ``La protein as a novel regulator of osteoclastogenesis.''
The Lupus autoantigen (La) protein is a master regulator of
osteoclasts. The technology involves a novel mechanism for precise
regulation of osteoclastogenesis through the manipulation of surface La
protein. The ability of osteoclasts to remodel bone can be modulated
by: (1) administering an effective amount of La protein or (2)
administering an agent that modulates La protein expression or
activity. Current solutions for bone diseases are usually broad-
spectrum treatments that either coat the skeletal system or inhibit
osteoclast development and these approaches can result in off-target
side effects. This technology's approach to regulating osteoclast
fusion and osteoclastogenesis by targeting the La protein should bypass
many side effects. The technology has been supported by conceptual in-
vitro data and lead optimization is ongoing; further research and
development are required to advance it towards disease-specific
preclinical and clinical stages.
Potential Commercial Application: Treatment of common and rare bone
diseases, including osteoporosis, Paget's disease of bone, fibrous
dysplasia, rheumatoid arthritis, osteopetrosis, osteomyelitis, or
metastatic bone disease.
Development Stage: In-vitro study completed and lead optimization
ongoing.
Dated: September 18, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2023-20479 Filed 9-20-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 21, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.